Reported Earnings • May 11
First quarter 2026 earnings released First quarter 2026 results: EPS: €0.11. Revenue: €1.70b (down 4.8% from 1Q 2025). Net income: €73.0m (up 22% from 1Q 2025). Profit margin: 4.3% (up from 3.3% in 1Q 2025). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. 공지 • Feb 25
Grifols, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026 Grifols, S.A. announced that they will report fiscal year 2025 results at 5:35 PM, Central European Standard Time on Feb 26, 2026 Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €9.98, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €18.75 per share. 공지 • Jan 09
Grifols, S.A. Announces Board Changes, Effective January 1, 2026 Grifols, S.A. Board of Directors resolved to unanimously approve, with effect from January 1, 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés, and the appointment of Mrs. Núria Martín Barnés as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán. Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €11.85, the stock trades at a forward P/E ratio of 14x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.17 per share. New Risk • Dec 14
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.8x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.8x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.7% average weekly change). New Risk • Nov 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.9% average weekly change). Valuation Update With 7 Day Price Move • Nov 24
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €9.33, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 7.8% over the past three years. Upcoming Dividend • Aug 04
Upcoming dividend of €0.12 per share Eligible shareholders must have bought the stock before 11 August 2025. Payment date: 13 August 2025. The company last paid an ordinary dividend in October 2014. The average dividend yield among industry peers is 2.1%. New Risk • Jul 31
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 3.0x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (3.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Large one-off items impacting financial results. Reported Earnings • Jul 30
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: €1.89b (up 4.0% from 2Q 2024). Net income: €117.1m (up €102.2m from 2Q 2024). Profit margin: 6.2% (up from 0.8% in 2Q 2024). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe. Board Change • Jun 25
High number of new directors Independent Director Pascal Ravery was the last director to join the board, commencing their role in 2024. 공지 • May 12
Grifols, S.A. to Report Q1, 2025 Results on May 12, 2025 Grifols, S.A. announced that they will report Q1, 2025 results on May 12, 2025 공지 • May 03
Grifols, S.A., Annual General Meeting, Jun 04, 2025 Grifols, S.A., Annual General Meeting, Jun 04, 2025. Location: parque empresarial can sant joan, avinguda de la generalitat, 152-158, 08174 sant cugat del valles, barcelona Spain Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to €8.18, the stock trades at a forward P/E ratio of 12x. Average trailing P/E is 21x in the Biotechs industry in Europe. Total loss to shareholders of 50% over the past three years. 
